Stock TRDA ENTRADA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Entrada Therapeutics, Inc.

Equities

TRDA

US29384C1080

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 29/04/2024 BST 		5-day change 1st Jan Change
12.34 USD -0.88% Intraday chart for Entrada Therapeutics, Inc. -5.80% -18.22%
03-13 Entrada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-13 Entrada Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Business Summary

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Company is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. VX-670 for dystrophy type 1 (DM1) is designed to block the triplet repeats in the messenger RNA (mRNA). ENTR-601-44 is in a Phase I clinical trial. The Company also announced the selection of additional clinical candidates within its Duchenne franchise, ENTR-601-45 and ENTR-601-50.

Number of employees: 159

Sales per Business

USD in Million2022Weight2023Weight Delta
Endosomal Escape Vehicle Therapeutics
100.0 %
0 nan % 129 100.0 % -

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 nan % 129 100.0 % -

Managers

Managers TitleAgeSince
Dipal Doshi CEO
 Chief Executive Officer 48 31/07/17
Kory Wentworth DFI
 Director of Finance/CFO 45 31/10/20
Nathan Dowden PSD
 President 54 03/11/19
Natarajan Sethuraman CTO
 Chief Tech/Sci/R&D Officer 62 31/08/17
Karla MacDonald PRN
 Corporate Officer/Principal - 31/05/21
Jared Cohen LAW
 General Counsel - 31/03/20
Kerry Robert HRO
 Human Resources Officer - -

Members of the board

Members of the board TitleAgeSince
Peter Kim BRD
 Director/Board Member 65 30/11/20
Mary Thistle BRD
 Director/Board Member 64 03/05/21
Gina Chapman BRD
 Director/Board Member 57 31/08/23
Dipal Doshi CEO
 Chief Executive Officer 48 31/07/17
Kush Parmar CHM
 Chairman 42 30/09/16
Bernhardt Zeiher BRD
 Director/Board Member 60 03/04/23

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 33,625,578 27,644,833 ( 82.21 %) 24,475 ( 0.0728 %) 82.21 %

Shareholders

NameEquities%Valuation
Baker Bros. Advisors LP
14.48 %
4,865,819 14.48 % 69 M $
MPM BioImpact, Inc
13.17 %
4,425,784 13.17 % 63 M $
5AM Venture Management LLC
13.12 %
4,408,379 13.12 % 62 M $
T. Rowe Price International Ltd.
8.957 %
3,009,673 8.957 % 43 M $
ROCHE HOLDING AG
8.167 %
2,744,120 8.167 % 39 M $
MERCK & CO., INC.
5.178 %
1,739,768 5.178 % 25 M $
BlackRock Advisors LLC
4.208 %
1,413,916 4.208 % 20 M $
Redmile Group LLC
3.821 %
1,283,735 3.821 % 18 M $
Vanguard Fiduciary Trust Co.
3.170 %
1,065,166 3.170 % 15 M $
Wellington Management Co. LLP
3.118 %
1,047,780 3.118 % 15 M $

Company contact information

Entrada Therapeutics, Inc.

One Design Center Place

02210, Boston

+

http://www.entradatx.com
address Entrada Therapeutics, Inc.(TRDA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Entrada Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
12.45 USD
Average target price
21 USD
Spread / Average Target
+68.67%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ENTRADA THERAPEUTICS, INC. Stock Entrada Therapeutics, Inc.
-18.22% 403M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.63% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.62% 95.28B
ARGENX SE Stock argenx SE
+1.46% 22.15B
BIONTECH SE Stock BioNTech SE
-16.67% 21.02B
GENMAB A/S Stock Genmab A/S
-8.58% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.74% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.21% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.41% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.57% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. TRDA Stock
  4. Company Entrada Therapeutics, Inc.